CC BY-NC-ND 4.0 · Pneumologie 2024; 78(01): 58-69
DOI: 10.1055/a-2161-0105
Review

E-cigarette use-associated lung injury (EVALI)

Lungenschädigungen, die mit E-Zigarettennutzung einhergehen (EVALI)
1   Medicina, Universidad Catolica de Cuenca Unidad Academica de Medicina y Ciencias de la Salud, Cuenca, Ecuador (Ringgold ID: RIN470028)
,
Claudia Gabriela Clavijo
1   Medicina, Universidad Catolica de Cuenca Unidad Academica de Medicina y Ciencias de la Salud, Cuenca, Ecuador (Ringgold ID: RIN470028)
,
Evelyn Fernanda Espinoza
1   Medicina, Universidad Catolica de Cuenca Unidad Academica de Medicina y Ciencias de la Salud, Cuenca, Ecuador (Ringgold ID: RIN470028)
,
Viviana Alexandra Tituana
2   Hospital Quality Manager, Hospital Humberto Molina, Zaruma, Ecuador
› Author Affiliations

Abstract

The prevalence of vaping has overtaken conventional cigarettes as the most frequent form of nicotine consumption among 15–24-year olds. There are currently a large number of both legitimate and illegitimate products and suppliers offering more than 8000 different flavors of vape on the market, whose additives are not tested, studied or regulated and whose safety and toxicity profile remains unknown. In vitro studies have demonstrated a dose-dependent decrease in the viability of normal human bronchial epithelial cells after exposure to vapor from electronic vape devices.

Short- and medium-term studies to date indicate that vapor-induced pulmonary lesions are the most serious and commonly reported side effect; such lesions include bilateral ground glass opacities in lung bases with subpleural preservation, bilateral infiltrates, pleural effusion, pneumomediastinum and nodular opacities. Cases of EVALI have been described in patients with daily exposure, as well as in users who reported having been exposed to these substances at least once a month. The most frequently inhaled substances are THC, flavored liquids of unknown content, and nicotine.

The clinical manifestations of dyspnea and cough are the most frequent respiratory symptomatology, in addition to constitutional manifestations such as fever and chills, and gastrointestinal manifestations such as vomiting, nausea, abdominal pain and diarrhea. To these can be added the presence of tachypnea, tachycardia, elevated blood pressure, hypoxia, leukocytosis with neutrophilia and elevated ESR.

Zusammenfassung

Das Dampfen hat die herkömmlichen Zigaretten als häufigste Form des Nikotinkonsums bei den 15- bis 24-Jährigen überholt. Derzeit gibt es auf dem Markt eine Vielzahl von legalen und illegalen Produkten und Anbietern, die mehr als 8000 verschiedene Geschmacksrichtungen anbieten, deren Zusatzstoffe nicht getestet, untersucht oder reguliert werden und deren Sicherheits- und Toxizitätsprofil unbekannt bleibt. In-vitro-Studien haben eine dosisabhängige Abnahme der Lebensfähigkeit normaler menschlicher Bronchialepithelzellen nach Exposition gegenüber Dampf aus elektronischen Verdampfungsgeräten gezeigt.

Bisherige kurz- und mittelfristige Studien deuten darauf hin, dass dampfinduzierte Lungenläsionen die schwerwiegendste und am häufigsten gemeldete Nebenwirkung sind. Zu diesen Läsionen gehören: bilaterale Mattigkeit in der Lungenbasis mit subpleuralem Erhalt, bilaterale Infiltrate, Pleuraerguss, Pneumomediastinum und knotige Trübungen. Fälle von EVALI wurden sowohl bei Patienten mit täglicher Exposition als auch bei Anwendern beschrieben, die angaben, diesen Substanzen mindestens einmal im Monat ausgesetzt gewesen zu sein. Die am häufigsten inhalierten Substanzen sind THC, aromatisierte Flüssigkeiten mit unbekanntem Inhalt und Nikotin.

Die klinischen Manifestationen von Dyspnoe und Husten sind die häufigsten respiratorischen Symptome, zusätzlich zu anderen konstitutionellen Manifestationen wie Fieber und Schüttelfrost und anderen gastrointestinalen Manifestationen wie Erbrechen, Übelkeit, Bauchschmerzen und Durchfall; hinzu kommt das Vorhandensein von Tachypnoe, Tachykardie, erhöhtem Blutdruck, Hypoxie, Leukozytose mit Neutrophilie und erhöhter ESR.



Publication History

Received: 26 May 2023

Accepted after revision: 13 July 2023

Article published online:
19 October 2023

© 2023. The Author(s). This is an open access article published by Thieme under the terms of the Creative Commons Attribution-NonDerivative-NonCommercial-License, permitting copying and reproduction so long as the original work is given appropriate credit. Contents may not be used for commercial purposes, or adapted, remixed, transformed or built upon. (https://creativecommons.org/licenses/by-nc-nd/4.0/).

Georg Thieme Verlag KG
Rüdigerstraße 14, 70469 Stuttgart, Germany

 
  • References

  • 1 Werner A, Koumans E, Chatham-Stephens K. et al. Hospitalizations and Deaths Associated with EVALI. N Engl J Med 2020; 382: 1589-1598
  • 2 Vogel B, Acevedo M, Appelman Y. et al. The Lancet women and cardiovascular disease Commission: reducing the global burden by 2030. Lancet 2021; 397: 2385-2438
  • 3 Wold L, Tarran R, Crotty Alexander L. et al. Cardiopulmonary Consequences of Vaping in Adolescents: A Scientific Statement From the American Heart Association. Circ Res 2022; 131: e70-e82
  • 4 Cao D, Aldy K, Hsu S. et al. Review of Health Consequences of Electronic Cigarettes and the Outbreak of Electronic Cigarette, or Vaping, Product Use-Associated Lung Injury. J Med Toxicol 2020; 16: 295-310
  • 5 Krishnasamy V, Hallowell B, Ko J. et al. Update: Characteristics of a Nationwide Outbreak of E-cigarette, or Vaping, Product Use-Associated Lung Injury – United States, August 2019-January 2020. MMWR Morb Mortal Wkly Rep 2020; 69: 90-94
  • 6 Jonas A, Raj R. Vaping-Related Acute Parenchymal Lung Injury: A Systematic Review. Chest 2020; 158: 1555-1565
  • 7 Sreeramareddy C, Acharya K, Manoharan A. Electronic cigarettes use and 'dual use' among the youth in 75 countries: estimates from Global Youth Tobacco Surveys (2014–2019). Sci Rep 2022; 12: 20967
  • 8 Gali K, Kastaun S, Pischke C. et al. Trends and consumption patterns in the use of e-cigarettes among adolescents and young adults in Germany (the DEBRA study). Addict Behav 2022; 133: 107375
  • 9 Orth B, Merkel C. Substance use among adolescents and young adults in Germany. Results of the Alcohol Survey 2021 on alcohol, smoking, cannabis and trends. BZgA research report. Cologne: Federal Center for Health Education 2022;
  • 10 Overbeek D, Kass A, Chiel L. et al. A review of toxic effects of electronic cigarettes/vaping in adolescents and young adults. Crit Rev Toxicol 2020; 50: 531-538
  • 11 Ellington S, Salvatore P, Ko J. et al. Update: Product, Substance-Use, and Demographic Characteristics of Hospitalized Patients in a Nationwide Outbreak of E-cigarette, or Vaping, Product Use-Associated Lung Injury – United States, August 2019-January 2020. MMWR Morb Mortal Wkly Rep 2020; 69: 44-49
  • 12 Rao D, Maple K, Dettori A. et al. Clinical Features of E-cigarette, or Vaping, Product Use-Associated Lung Injury in Teenagers. Pediatr Radiol 2020; 50: 338-344
  • 13 Yale University. E-cigarette, or Vaping Product, Use Associated Lung Injury (EVALI) (July 2020). Accessed May 15, 2023 at: https://www.yalemedicine.org/conditions/evali
  • 14 Winnicka L, Shenoy M. EVALI and the Pulmonary Toxicity of Electronic Cigarettes: A Review. J Gen Intern Med 2020; 35: 2130-2135
  • 15 Ciapponi A, Cairoli F, Solioz G. et al. Switching from cigarettes to electronic nicotine delivery system: Rapid Systematic Review and Meta-analysis and economic aspects. Rev Peru Med Exp Salud Publica 2021; 38: 537-550
  • 16 Su V, Chen W, Yu W. et al. The main e-cigarette component vegetable glycerin enhances neutrophil migration and fibrosis in endotoxin-induced lung injury via p38 MAPK activation.  Respir Res 2023; 24: 9
  • 17 Kligerman S, Raptis C, Larsen B. et al. Radiologic, Pathologic, Clinical, and Physiologic Findings of Electronic Cigarette or Vaping Product Use-associated Lung Injury (EVALI): Evolving Knowledge and Remaining Questions. Radiology 2020; 294: 491-505
  • 18 Qasim H, Karim Z, Rivera J. et al. Impact of Electronic Cigarettes on the Cardiovascular System. J Am Heart Assoc 2017; 6
  • 19 Marrocco A, Singh D, Christiani D. et al. E-cigarette vaping associated acute lung injury (EVALI): state of science and future research needs.  Crit Rev Toxicol 2022; 52: 188-220
  • 20 Shin Y, Hunt D, Akwe J. An Epidemic Supplanted by a Pandemic: Vaping-Related Illness and COVID-19. South Med J 2022; 115: 8-12
  • 21 Mulligan K, Zheng D, Gallo Marin B. et al. COVID-19 and EVALI: Considerations regarding two concurrent public health crises. Am J Emerg Med 2022; 56: 389-390
  • 22 Besaratinia A, Tommasi S. The consequential impact of JUUL on youth vaping and the landscape of tobacco products: The state of play in the COVID-19 era. Prev Med Rep 2021; 22: 101374
  • 23 Bakaloudi D, Evripidou K, Siargkas A. et al. Impact of COVID-19 lockdown on smoking and vaping: systematic review and meta-analysis. Public Health 2023; 218: 160-172
  • 24 Gaiha S, Cheng J, Halpern-Felsher B. Association Between Youth Smoking, Electronic Cigarette Use, and COVID-19. J Adolesc Health 2020; 67: 519-523
  • 25 Kaur G, Lungarella G, Rahman I. SARS-CoV-2 COVID-19 susceptibility and lung inflammatory storm by smoking and vaping. J Inflamm (Lond) 2020; 17: 21
  • 26 Singhal S, Degano C, Berenbaum E. et al. Does Vaping Increase the Risk of COVID-19 Transmission and Make Individuals Who Vape Susceptible to Infection and Prone to Severe Illness? A Review. J Can Dent Assoc 2022; 88: m1
  • 27 Martin E, Clapp P, Rebuli M. et al. E-cigarette use results in suppression of immune and inflammatory-response genes in nasal epithelial cells similar to cigarette smoke. Am J Physiol Lung Cell Mol Physiol 2016; 311: L135-L144
  • 28 Rebuli M, Glista-Baker E, Hoffman J. et al. Electronic-Cigarette Use Alters Nasal Mucosal Immune Response to Live-attenuated Influenza Virus. A Clinical Trial. Am J Respir Cell Mol Biol 2021; 64: 126-137
  • 29 Reidel B, Radicioni G, Clapp P. et al. E-Cigarette Use Causes a Unique Innate Immune Response in the Lung, Involving Increased Neutrophilic Activation and Altered Mucin Secretion. Am J Respir Crit Care Med 2018; 197: 492-501
  • 30 Brar E, Saxena A, Dukler C. et al. Vaping, SARS-CoV-2, and Multisystem Inflammatory Syndrome: A Perfect Storm. Front Pediatr 2021; 9: 647925
  • 31 Sharma P, Sheikh T, Williams C. Electronic Vaping Product Use Among Adolescents in the Era of the COVID-19 Pandemic: An Updated Scientific Review for Clinicians. WMJ 2021; 120: 205-208
  • 32 Foust AM, Winant AJ, Chu WC. et al. Pediatric SARS, H1N1, MERS, EVALI, and Now Coronavirus Disease (COVID-19) Pneumonia: What Radiologists Need to Know. AJR Am J Roentgenol 2020; 215: 736-744
  • 33 Friedman J, Schooler G, Kwon J. et al. Pediatric electronic cigarette or vaping product use-associated lung injury (EVALI): updates in the coronavirus disease 2019 (COVID-19) pandemic era. Pediatr Radiol 2022; 52: 2009-2016
  • 34 Chatham-Stephens K, Roguski K, Jang Y. et al. Characteristics of Hospitalized and Nonhospitalized Patients in a Nationwide Outbreak of E-cigarette, or Vaping, Product Use-Associated Lung Injury – United States, November 2019.  MMWR Morb Mortal Wkly Rep 2019; 68: 1076-1080
  • 35 Aldy K, Cao D, Weaver M. et al. E-cigarette or vaping product use-associated lung injury (EVALI) features and recognition in the emergency department. J Am Coll Emerg Physicians 2020; 1: 1090-1096
  • 36 Shinbashi M, Rubin B. Electronic cigarettes and e-cigarette/vaping product use associated lung injury (EVALI). Paediatr Respir Rev 2020; 36: 87-91
  • 37 Layden J, Ghinai I, Pray I. et al. Pulmonary Illness Related to E-Cigarette Use in Illinois and Wisconsin – Final Report. N Engl J Med 2020; 382: 903-916
  • 38 Chaumont M, de Becker B, Zaher W. et al. Differential Effects of E-Cigarette on Microvascular Endothelial Function, Arterial Stiffness and Oxidative Stress: A Randomized Crossover Trial. Sci Rep 2018; 8: 10378
  • 39 Kligerman S, Kay F, Raptis C. et al. CT Findings and Patterns of e-Cigarette or Vaping Product Use-Associated Lung Injury: A Multicenter Cohort of 160 Cases. Chest 2021; 160: 1492-1511
  • 40 Zou R, Tiberio P, Triantafyllou G. et al. Clinical Characterization of E-Cigarette, or Vaping, Product Use-associated Lung Injury in 36 Patients in Pittsburgh, Pennsylvania. Am J Respir Crit Care Med 2020; 201: 1303-1306
  • 41 Adkins S, Anderson K, Goodman A. et al. Demographics, Substance Use Behaviors, and Clinical Characteristics of Adolescents With e-Cigarette, or Vaping, Product Use-Associated Lung Injury (EVALI) in the United States in 2019. JAMA Pediatr 2020; 174: e200756
  • 42 Artunduaga M, Rao D, Friedman J. et al. Pediatric Chest Radiographic and CT Findings of Electronic Cigarette or Vaping Product Use-associated Lung Injury (EVALI). Radiology 2020; 295: 430-438
  • 43 Heinzerling A, Armatas C, Karmarkar E. et al. Severe Lung Injury Associated With Use of e-Cigarette, or Vaping, Products-California, 2019. JAMA Intern Med 2020; 180: 861-869
  • 44 Blagev D, Harris D, Dunn A. et al. Clinical presentation, treatment, and short-term outcomes of lung injury associated with e-cigarettes or vaping: a prospective observational cohort study. Lancet 2019; 394: 2073-2083
  • 45 Tzortzi A, Kapetanstrataki M, Evangelopoulou V. et al. A Systematic Literature Review of E-Cigarette-Related Illness and Injury: Not Just for the Respirologist. Int J Environ Res Public Health 2020; 17: 2248
  • 46 Gentzke A, Creamer M, Cullen K. et al. Vital Signs: Tobacco Product Use Among Middle and High School Students – United States, 2011–2018. MMWR Morb Mortal Wkly Rep 2019; 68: 157-164
  • 47 Kalininskiy A, Bach C, Nacca N. et al. E-cigarette, or vaping, product use associated lung injury (EVALI): case series and diagnostic approach. Lancet Respir Med 2019; 7: 1017-1026
  • 48 Sreedharan S, Mian M, Robertson R. et al. Radiological findings of e-cigarette or vaping product use associated lung injury: A systematic review.  Heart Lung 2021; 50: 736-741
  • 49 Antoniewicz L, Brynedal A, Hedman L. et al. Acute Effects of Electronic Cigarette Inhalation on the Vasculature and the Conducting Airways. Cardiovasc Toxicol 2019; 19: 441-450
  • 50 Siegel D, Jatlaoui T, Koumans E. et al. Update: Interim Guidance for Health Care Providers Evaluating and Caring for Patients with Suspected E-cigarette, or Vaping, Product Use Associated Lung Injury – United States, October 2019. MMWR Morb Mortal Wkly Rep 2019; 68: 919-927
  • 51 Aberegg S, Cirulis M, Maddock S. et al. Clinical, Bronchoscopic, and Imaging Findings of e-Cigarette, or Vaping, Product Use-Associated Lung Injury Among Patients Treated at an Academic Medical Center. JAMA Netw Open 2020; 3: e2019176
  • 52 Davidson K, Brancato A, Heetderks P. et al. Outbreak of Electronic-Cigarette-Associated Acute Lipoid Pneumonia – North Carolina, July-August 2019. MMWR Morb Mortal Wkly Rep 2019; 68: 784-786
  • 53 Maddock S, Cirulis M, Callahan S. et al. Pulmonary Lipid-Laden Macrophages and Vaping. N Engl J Med 2019; 381: 1488-1489
  • 54 Alzghoul B, Innabi A, Mukhtar F. et al. Rapid Resolution of Severe Vaping-induced Acute Lipoid Pneumonia after Corticosteroid Treatment. Am J Respir Crit Care Med 2020; 202: e32-e33